Indian Health Ministers Would Impose Price Controls on All ‘Essential’ Generic Drugs
An Indian panel of government health ministers has recommended price controls be applied to all 348 generic drugs on the country’s essential generic drugs list. The recommendation is somewhat positive for industry, since the proposed controls would peg prices to an average sales price formula rather than a fixed government-determined price.
The health ministers have submitted their final proposal on what drugs should be covered and how prices will be set by the National Pharmaceutical Pricing Authority to the Indian cabinet, Chinu Srinivasan, joint convener of the All India Drug Action Network, whose petition on the issue triggered Supreme Court hearings, said.
A decision to include all 348 generic products on the essential drugs list would have a sizable impact on the industry, placing price controls on about 60 percent to 70 percent of the generic drug market, according to reports from those on the ground in India, said Amy Hariani, director and legal policy counsel at the U.S.-India Business Council. Currently, only 74 generics are subject to mandatory price controls.
What does that mean for generic-drug makers in India? What about U.S. manufacturers doing business in India?
Every month for more than 35 years, the International Pharmaceutical Regulatory Monitor has kept professionals on top of key changes in pharmaceutical regulation around the world, covering rules and standards from the FDA, the European Medicines Agency, Health Canada, Australia’s Therapeutic Goods Administration, the International Conference on Harmonisation and other agencies in Europe, Japan and across the globe.
Get full official English-language texts of important, hard-to-obtain proposals, regulations, rules, directives, guidances and other documents to help you prepare better-documented, properly formatted drug applications for fastest processing. Subscribe to this monthly publication today!
Come for this valuable opportunity to hear FDA officials discuss regulatory plans and objectives — and ask questions you need answered; learn from device industry experts, consultants and other experts with actionable tips and strategies you can take straight back to the office; and network with other professionals who understand your challenges; share war stories and insights over a drink. Register Today.Read More
The FDA's new enforcement plan makes one thing clear: Developing a successful CAPA program has never been more important. But creating an FDA-proof CAPA isn’t easy. If only you could pick the brain of someone who is coping successfully with CAPA — the best and the brightest, an industry leader who has devised programs, procedures and solutions that have put companies out in front with the FDA. Well, you can. Register today.Read More
The FDA’s cadre of freshly trained inspectors — many of whom come directly from industry — and increased focus on specialized inspections are making it harder than ever to predict the outcome of your next FDA inspection. Unless, of course, you have Surviving an FDA Inspection at your fingertips. If you could spend less than $400 to get your drug manufacturing facility fully prepared to face a tough inspection by the FDA, would you even hesitate? ... Of course not!